XILIO THERAPEUTICS, INC.(XLO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

XLO XILIO THERAPEUTICS, INC.

休市中 09-11 16:00:00 EDT

8.93

+0.00

0.00%

盘后8.68

-0.25-2.80%

18:59 EDT

最高9.49	最低8.93	成交量5,142
今开8.93	昨收8.93	日振幅6.27%
总市值5,876万	流通市值3,038万	总股本658.02万
成交额4.74万	换手率0.15%	流通股本340.25万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"XLO","market":"US","secType":"STK","nameCN":"XILIO THERAPEUTICS, INC.","latestPrice":8.93,"timestamp":1789156800000,"preClose":8.93,"halted":0,"volume":5142,"hourTrading":{"tag":"盘后","latestPrice":8.68,"preClose":8.93,"latestTime":"18:59 EDT","volume":161,"amount":1400.38,"timestamp":1789167577265,"change":-0.25,"changeRate":-0.027996,"amplitude":0.027996},"delay":0,"changeRate":0,"floatShares":3402500,"shares":6580153,"eps":-3.3174,"marketStatus":"休市中","change":0,"latestTime":"09-11 16:00:00 EDT","open":8.93,"high":9.49,"low":8.93,"amount":47364.699995999996,"amplitude":0.06271,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.3174,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1634875200000,"exchange":"NASDAQ","adjPreClose":8.93,"preHourTrading":{"tag":"盘前","latestPrice":8.68,"preClose":8.93,"latestTime":"07:17 EDT","volume":2,"amount":17.36,"timestamp":1789125446150,"change":-0.25,"changeRate":-0.027996,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":8.68,"preClose":8.93,"latestTime":"18:59 EDT","volume":161,"amount":1400.38,"timestamp":1789167577265,"change":-0.25,"changeRate":-0.027996,"amplitude":0.027996},"volumeRatio":0.5720160003777728},"requestUrl":"/m/hq/s/XLO","defaultTab":"news","newsList":[{"id":"1198782677","title":"Xilio Therapeutics 计划于2027年下半年公布转移性非小细胞肺癌患者初步1期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1198782677","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198782677?lang=zh_cn&edition=full","pubTime":"2026-08-12 19:32","pubTimestamp":1786534371,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics 宣布，计划在2027年下半年公布其针对转移性非小细胞肺癌（NSCLC）患者的初步1期临床试验数据。这一消息标志着该公司在肿瘤治疗领域迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120181621","title":"Xilio Therapeutics公布2026年第二季度财务业绩，并更新管线与业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1120181621","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120181621?lang=zh_cn&edition=full","pubTime":"2026-08-12 19:31","pubTimestamp":1786534269,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics（股票代码：XLO）——这家专注于肿瘤免疫疗法的生物科技公司，于近日正式披露了其2026年第二季度的财务数据。与此同时，该公司还同步更新了其研发管线的进展以及整体业务运营的最新动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187615520","title":"Xilio Therapeutics 与 Leerink Partners 签订销售协议 或发售最多1722万美元普通股 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1187615520","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187615520?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:53","pubTimestamp":1778586788,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会的文件显示，生物技术公司Xilio Therapeutics Inc. 已与投资银行Leerink Partners LLC签订了一项普通股销售协议。依据该协议，Xilio Therapeutics 可能通过“按市价”发行方式，不定期地发售和出售总价值最高达1722万美元的公司普通股。Leerink Partners将作为销售代理，负责相关股票的发售事宜。此次潜在发售所得款项将用于公司一般企业用途，可能包括推进其肿瘤免疫疗法产品线的研发、临床试验以及其他运营开支。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195745157","title":"Xilio Therapeutics任命Cheryl R. Blanchard博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1195745157","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195745157?lang=zh_cn&edition=full","pubTime":"2026-04-16 19:33","pubTimestamp":1776339227,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2026年4月16日——临床阶段生物技术公司Xilio Therapeutics, Inc.今日宣布，任命Cheryl R. Blanchard博士加入公司董事会。公司同时公告，Christina Rossi已于2026年4月15日卸任董事职务。Cheryl R. Blanchard博士为Xilio带来逾30年领导经验，在生命科学企业具备深厚的科研、运营与商业管理背景。Xilio Therapeutics是一家临床阶段生物技术公司，致力于研发掩蔽型免疫肿瘤疗法，旨在显著提升癌症患者疗效的同时避免现有治疗引发的全身性副作用。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","XLO","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119119277","title":"Leerink Partners因1股合14股的反向拆股将Xilio Therapeutics目标价从2美元调整为20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119119277","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119119277?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:29","pubTimestamp":1774355355,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布，因XILIO THERAPEUTICS, INC.实施1股合14股的反向拆股，已将其目标股价从原先的2美元上调至20美元。此次调整旨在反映拆股后公司股本结构的变化。\n反向拆股通常由股价较低的企业采用，旨在提升每股交易价格。尽管目标价数字表面出现大幅上调，但实际估值水平并未发生实质性改变。分析师指出，这类技术性调整需结合公司基本面及研发进展进行综合评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510377483","title":"Xilio Therapeutics(XLO)盘前涨超114% 与艾伯维达成合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2510377483","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510377483?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:10","pubTimestamp":1739369403,"startTime":"0","endTime":"0","summary":"金吾财讯 | Xilio Therapeutics(XLO)盘前涨超114%，报1.42美元。消息面上，艾伯维公司与Xilio Therapeutics签署了一份潜在价值超过20亿的合作和许可选择协议，旨在为Xilio提供支持。两家公司将共同开发新的肿瘤激活抗体免疫疗法。Xilio将获得5200万美元的预付款，还将有资格获得额外的21亿美元，以覆盖与选择相关的费用和里程碑以及产品销售的版税。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/ZDg5MDljMjM3Zjg4MTM1NjQzMDIzNjY=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDg5MDljMjM3Zjg4MTM1NjQzMDIzNjY=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"285376","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xiliotx.com","stockEarnings":[{"period":"1week","weight":-0.0078},{"period":"1month","weight":-0.0133},{"period":"3month","weight":0.0746},{"period":"6month","weight":0.2505},{"period":"1year","weight":-0.1259},{"period":"ytd","weight":-0.0037}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Xilio Therapeutics, Inc.于2020年6月18日在特拉华州注册成立。该公司是一家临床阶段的生物技术公司，发现并开发掩蔽免疫生态学（I-O）疗法，旨在显著改善癌症患者的预后。利用其临床验证的掩蔽技术和能力，该公司正在开发I-O疗法，旨在在肿瘤微环境中选择性激活，以实现持久疗效，而不会产生与系统活性I-O药物相关的严重副作用。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.011356},{"month":2,"riseRate":0.4,"avgChangeRate":0.023701},{"month":3,"riseRate":0.4,"avgChangeRate":-0.012363},{"month":4,"riseRate":0.4,"avgChangeRate":-0.099597},{"month":5,"riseRate":0.6,"avgChangeRate":0.055632},{"month":6,"riseRate":0.2,"avgChangeRate":-0.104505},{"month":7,"riseRate":0.4,"avgChangeRate":-0.001524},{"month":8,"riseRate":0.4,"avgChangeRate":-0.051868},{"month":9,"riseRate":0.4,"avgChangeRate":0.030784},{"month":10,"riseRate":0.5,"avgChangeRate":0.099935},{"month":11,"riseRate":0.2,"avgChangeRate":-0.160439},{"month":12,"riseRate":0.4,"avgChangeRate":-0.10922}],"exchange":"NASDAQ","name":"XILIO THERAPEUTICS, INC.","nameEN":"XILIO THERAPEUTICS, INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"XILIO THERAPEUTICS, INC.(XLO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供XILIO THERAPEUTICS, INC.(XLO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"XILIO THERAPEUTICS, INC.,XLO,XILIO THERAPEUTICS, INC.股票,XILIO THERAPEUTICS, INC.股票老虎,XILIO THERAPEUTICS, INC.股票老虎国际,XILIO THERAPEUTICS, INC.行情,XILIO THERAPEUTICS, INC.股票行情,XILIO THERAPEUTICS, INC.股价,XILIO THERAPEUTICS, INC.股市,XILIO THERAPEUTICS, INC.股票价格,XILIO THERAPEUTICS, INC.股票交易,XILIO THERAPEUTICS, INC.股票购买,XILIO THERAPEUTICS, INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"XILIO THERAPEUTICS, INC.(XLO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供XILIO THERAPEUTICS, INC.(XLO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}